Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial

Nattaphol Uransilp, Pannawat Chaiyawatthanananthn, Sombat Muengtaweepongsa, Nattaphol Uransilp, Pannawat Chaiyawatthanananthn, Sombat Muengtaweepongsa

Abstract

Backgrounds: Stroke is the leading cause of death and long-term disability. Oxidative stress is elevated during occurrence of acute ischemic stroke (AIS). Soluble LOX-1 (sLOX-1) and NO are used as biomarkers for vascular oxidative stress that can reflect stabilization of atherosclerotic plaque. Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression.

Objectives: To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin.

Methods: 65 patients with AIS within 24 hours after onset were randomized to treatment with simvastatin 10 mg/day or 40 mg/day for 90 days. Personal data and past history of all patients were recorded at baseline. The blood chemistries were measured by standard laboratory techniques. Serum sLOX-1 and NO levels and neurological outcomes including NIHSS, mRS, and Barthel index were tested at baseline and Day 90 after simvastatin therapy.

Results: Baseline characteristics were not significantly different in both groups except history of hypertension. Serum sLOX-1 and NO levels significantly reduce in both groups (sLOX-1 = 1.19 ± 0.47 and 0.98 ± 0.37 ng/ml; NO = 49.28 ± 7.21 and 46.59 ± 9.36 μmol/l) in 10 mg/day and 40 mg/day simvastatin groups, respectively. Neurological outcomes including NIHSS, mRS, and Barthel index significantly improve in both groups. However, no difference in NO level and neurological outcomes was found at 90 days after treatment as compared between low dose 10 mg/day and high dose 40 mg/day of simvastatin.

Conclusion: High-dose simvastatin might be helpful to reduce serum sLOX-1. But no difference in clinical outcomes was found between high- and low-dose simvastatin. Further more intensive clinical trial is needed to confirm the appropriate dosage of simvastatin in patients with acute ischemic stroke. This trial is registered with ClinicalTrials.gov ID: NCT03402204.

Figures

Figure 1
Figure 1
Serum sLOX-1 (a) and NO (b) levels of patients with acute ischemic stroke that compare simvastatin 10 mg/day and 40 mg/day at Day 90 after simvastatin treatment. ∗P < 0.05.

References

    1. Lopez A. D., Mathers C. D., Ezzati M., Jamison D. T., Murray C. J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. The Lancet. 2006;367(9524):1747–1757. doi: 10.1016/S0140-6736(06)68770-9.
    1. Stroke epidemiological data of nine Asian countries. Asian Acute Stroke Advisory Panel (AASAP) J Med Assoc Thai. 2000;83(1):1–7.
    1. Poungvarin N. Burden of stroke in Thailand. International Journal of Stroke. 2007;2(2):127–128. doi: 10.1111/j.1747-4949.2007.00104.x.
    1. Hanchaiphiboolkul S., Poungvarin N., Nidhinandana S., et al. Prevalence of stroke and stroke risk factors in thailand: Thai epidemiologic stroke (TES) study. Journal of the Medical Association of Thailand. 2011;94(4):427–436.
    1. Palangrit S., Muengtaweepongsa S. Risk factors of stroke in Pathumthani Province, Thailand. Journal of the Medical Association of Thailand. 2015;98(7):649–655.
    1. Suwanwela N. C. Stroke epidemiology in Thailand. Journal of Stroke. 2014;16(1):1–7. doi: 10.5853/jos.2014.16.1.1.
    1. Sies H. Oxidative stress: oxidants and antioxidants. Experimental Physiology. 1997;82(2):291–295. doi: 10.1113/expphysiol.1997.sp004024.
    1. Chaiyawatthanananthn P., Suwanprasert K., Muengtaweepongsa S. Differentiation of serum sLOX-1 and NO levels in acute ischemic stroke patients with internal carotid artery stenosis and those without internal carotid artery stenosis. Journal of the Medical Association of Thailand. 2016;99:S48–S53.
    1. Atik İ., Kozacı N., Beydilli İ., Avcı M., Ellidağ H., Keşaplı M. Investigation of oxidant and antioxidant levels in patients with acute stroke in the emergency service. The American Journal of Emergency Medicine. 2016;34(12):2379–2383. doi: 10.1016/j.ajem.2016.08.062.
    1. Brinkley T. E., Kume N., Mitsuoka H., et al. Variation in the human lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) gene is associated with plasma soluble LOX-1 levels. Experimental Physiology. 2008;93(9):1085–1090. doi: 10.1113/expphysiol.2008.042267.
    1. Li X., Jin P., Xue J., et al. Role of sLOX-1 in intracranial artery stenosis and in predicting long-term prognosis of acute ischemic stroke. Brain and Behavior. 2018;8(1):p. e00879. doi: 10.1002/brb3.879.
    1. Caglar I. M., Ozde C., Biyik I., et al. Association between soluble lectin-like oxidized low-density lipoprotein receptor 1 levels and coronary slow flow phenomenon. Archives of Medical Science. 2016;12(1):31–37. doi: 10.5114/aoms.2015.51412.
    1. Chen Z.-Q., Mou R.-T., Feng D.-X., Wang Z., Chen G. The role of nitric oxide in stroke. Medical Gas Research. 2017;7(3):194–203. doi: 10.4103/2045-9912.215750.
    1. Sabri M., Ai J., Marsden P. A., Macdonald R. L. Simvastatin re-couples dysfunctional endothelial nitric oxide synthase in experimental subarachnoid hemorrhage. PLoS ONE. 2011;6(2) doi: 10.1371/journal.pone.0017062.e17062
    1. Zhang Z., Zhang M., Li Y., et al. Simvastatin inhibits the additive activation of ERK1/2 and proliferation of rat vascular smooth muscle cells induced by combined mechanical stress and oxLDL through LOX-1 pathway. Cellular Signalling. 2013;25(1):332–340. doi: 10.1016/j.cellsig.2012.10.006.
    1. Cuccurullo C., Iezzi A., Fazia M. L., et al. Suppression of rage as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(12):2716–2723. doi: 10.1161/01.ATV.0000249630.02085.12.
    1. Zhao J., Zhang X., Dong L., Wen Y., Cui L. The many roles of statins in ischemic stroke. Current Neuropharmacology. 2014;12(6):564–574. doi: 10.2174/1570159X12666140923210929.
    1. Investigators TSPbARiCL. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. New England Journal of Medicine. 2006;355(6):549–959.
    1. Chen H., Li D., Sawamura T., Inoue K., Mehta J. L. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: Modulation by losartan. Biochemical and Biophysical Research Communications. 2000;276(3):1100–1104. doi: 10.1006/bbrc.2000.3532.
    1. Taye A., Saad A. H., Kumar A. H., Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. European Journal of Pharmacology. 2010;627(1–3):42–48. doi: 10.1016/j.ejphar.2009.10.045.
    1. Hu C., Dandapat A., Sun L., et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension. 2008;52(3):556–562. doi: 10.1161/HYPERTENSIONAHA.108.115287.
    1. Brinkley T. E., Kume N., Mitsuoka H., Phares D. A., Hagberg J. M. Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity. 2008;16(6):1454–1456. doi: 10.1038/oby.2008.213.
    1. Li D., Mehta J. L. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101(25):2889–2895. doi: 10.1161/01.cir.101.25.2889.
    1. Kume N., Kita T. Apoptosis of Vascular Cells by Oxidized LDL: Involvement of Caspases and LOX-1 and Its Implication in Atherosclerotic Plaque Rupture. Circulation Research. 2004;94(3):269–270. doi: 10.1161/01.RES.0000119804.92239.97.
    1. Smirnova I. V., Kajstura M., Sawamura T., Goligorsky M. S. Asymmetric dimethylarginine upregulates LOX-1 in activated macrophages: role in foam cell formation. American Journal of Physiology-Heart and Circulatory Physiology. 2004;287(2):H782–H790. doi: 10.1152/ajpheart.00822.2003.
    1. Li D., Liu L., Chen H., Sawamura T., Ranganathan S., Mehta J. L. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003;107(4):612–617. doi: 10.1161/01.CIR.0000047276.52039.FB.
    1. Schwarz D. A., Barry G., Mackay K. B., et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Research. 2002;101(1-2):12–22. doi: 10.1016/S0169-328X(02)00135-3.
    1. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proceedings of the National Acadamy of Sciences of the United States of America. 1998;95(15):8880–8885. doi: 10.1073/pnas.95.15.8880.
    1. Chen J., Zhang Z. G., Li Y., et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Annals of Neurology. 2003;53(6):743–751. doi: 10.1002/ana.10555.
    1. Moonis M., Kumar R., Henninger N., Kane K., Fisher M. Pre and post-stroke use of statins improves stroke outcome. Indian Journal of Community Medicine. 2014;39(4):214–217. doi: 10.4103/0970-0218.143021.
    1. Kuwashiro T., Sugimori H., Ago T., Kuroda J., Kamouchi M., Kitazono T. The impact of predisposing factors on long-term outcome after stroke in diabetic patients: the Fukuoka Stroke Registry. European Journal of Neurology. 2013;20(6):921–927. doi: 10.1111/ene.12100.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj